Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 33Breast Neoplasms 25Colorectal Neoplasms 20Prostatic Neoplasms 18Uterine Cervical Neoplasms 13Anxiety Disorders 13Brain Neoplasms 7Urinary Bladder Neoplasms 6Lymphoma, Follicular 6Lung Neoplasms 6Colonic Neoplasms 6Pain 5Depression 5Carcinoma, Hepatocellular 5Uterine Cervical Dysplasia 4Ovarian Neoplasms 4Motor Activity 4Inflammation 4Head and Neck Neoplasms 4Epilepsy 4Dementia 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Smoking 3Sarcoma 3Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Neoplastic Syndromes, Hereditary 3Lymphoma 3

Interventions

pembrolizumab 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Enrolling by invitation × Malignant Ascites × Clear all
NCT05745233 2023-08-24

Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites

China Medical University Hospital

Phase NA Enrolling by invitation
30 enrolled

Malignant Ascites

Data powered by HemOnc (CC BY 4.0) Colophon âš¡